Table 2 Healthcare resource utilization and annual costs during the baseline period
Patients with T2D | Patients with CVD | ||||||
|---|---|---|---|---|---|---|---|
With comorbid MDD (n = 11,446) | Without comorbid MDD (n = 11,446) | P value | With comorbid MDD (n = 14,149) | Without comorbid MDD (n = 14,149) | P value | ||
Baseline average duration of analysis, months | |||||||
Mean (SD) | 43.1 (28.9) | 43.1 (28.0) | 0.99 | 42.8 (29.8) | 43.4 (29.6) | 0.11 | |
All-cause healthcare resource utilization during the baseline period, n (%) | |||||||
Proportion of patients requiring: | |||||||
Hospitalizations | 1222 (10.7) | 872 (7.6) | < 0.0001 | 2250 (15.9) | 1606 (11.4) | < 0.0001 | |
ED visits | 4368 (38.2) | 3890 (34.0) | < 0.0001 | 7121 (50.3) | 6431 (45.5) | < 0.0001 | |
Outpatient visits | 10,777 (94.2) | 10,606 (92.7) | < 0.0001 | 13,887 (98.1) | 13,786 (97.4) | < 0.0001 | |
Annual all-cause costs during the baseline period, $ | |||||||
Pharmacy | |||||||
Mean (SD) | 1859 (6203) | 1206 (4265) | < 0.0001 | 2498 (6931) | 1775 (7679) | < 0.0001 | |
Medical | |||||||
Mean (SD) | 6127 (20,069) | 4484 (15,874) | < 0.0001 | 8112 (22,857) | 6335 (23,142) | < 0.0001 | |
Total | |||||||
Mean (SD) | 7986 (22,158) | 5689 (17,467) | < 0.0001 | 10,610 (25,425) | 8110 (25,077) | < 0.0001 | |